+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Coagulation Factor Concentrates Market - Global Forecast 2026-2032- Product Image
Coagulation Factor Concentrates Market - Global Forecast 2026-2032- Product Image
New

Coagulation Factor Concentrates Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 185 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5887478
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The coagulation factor concentrates market is undergoing a period of accelerated change, shaped by ongoing innovation in biologics, shifting regulatory priorities, and a sharpened emphasis on reliable supply networks. Senior decision-makers are challenged to coordinate clinical, operational, and strategic responses to secure market position and ensure dependable access for patients worldwide.

Market Snapshot: Coagulation Factor Concentrates Market

The Coagulation Factor Concentrates Market grew from USD 9.59 billion in 2025 to USD 10.40 billion in 2026. It is expected to continue growing at a CAGR of 8.64%, reaching USD 17.14 billion by 2032. This growth reflects greater product innovation, rising adoption of therapies for both inherited and acquired bleeding disorders, and strengthening supply chain dependability. Increasing engagement from payers and a focus on patient-centric care models are supporting this expansion as well. The market is being shaped by dynamic interplay among product development, evolving reimbursement environments, and provider-payer collaborations, presenting both challenges and opportunities for industry stakeholders.

Scope & Segmentation

  • Product Types: Plasma-derived concentrates, recombinant factor products, extended half-life variants, and standard half-life formulations. Each addresses specific therapy gaps and patient populations, allowing for differentiation based on innovation and manufacturing complexity.
  • Clinical Indications: Hemophilia A, Hemophilia B, and Von Willebrand Disease. Protocols are increasingly tailored for varied severity and subtypes, with dosing strategies and clinical guidelines evolving to reflect new evidence and best practices.
  • Formulations: Liquid and lyophilized powder forms. These address facility capabilities with options for improved storage, transport, and administration efficiency.
  • End Users: Hospitals, specialty treatment centers, and pharmacy channels. Each end user demonstrates distinct procurement processes, clinical requirements, and patient management models.
  • Distribution Channels: Hospital pharmacies, online and retail pharmacies. These play roles in managing logistical hurdles and reimbursement needs, influencing accessibility and cost structures.
  • Administration Route: Intravenous infusion. Safety, precision in management, and adoption of device-assisted delivery methods are central to this segment.
  • Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific. Each region presents unique regulatory frameworks, market access challenges, and demand trends, impacting launch strategies and resource allocation.
  • Technology Levers: Recombinant engineering, cold-chain management, digital adherence tools, and remote monitoring solutions. These initiatives drive efficiency in production, logistics, and patient outcomes, underlining the importance of continuous process innovation.

Key Takeaways

  • Clinical improvements in product properties are simplifying patient management and enhancing adherence, supporting long-term outcomes and the alignment of protocols across care settings.
  • Healthcare organizations are evolving their procurement strategies to meet cost, supply continuity, and evidence-based outcome targets, directly influencing competitive differentiation and contracting opportunities.
  • Operational models incorporate decentralized manufacturing and advanced cold-chain solutions to protect market access. These strategies also support rapid response to emergent market changes.
  • Manufacturers address diverse patient segment needs, from cases with severe clotting factor deficiencies to complex bleeding disorders, by developing adaptive dosing, support services, and evidence-informed treatment protocols.
  • Regulatory harmonization, active surveillance post-market, and ongoing shifts in reimbursement policies create additional complexity for successful market entry, especially with the launch of novel biologic products.
  • The adoption of digital therapeutics, enhanced support for infusion management, and data-driven insights strengthen connectivity among manufacturers, payers, and treatment providers, advancing real-world effectiveness.

Tariff Impact: Navigating Policy Change in the United States

Recent U.S. tariff adjustments have fundamentally shifted global supply strategies for coagulation factor concentrates. Leading manufacturers are accelerating localization efforts, expanding contract manufacturing agreements, and increasing supply chain flexibility to ensure continuity of care. Procurement teams have responded by updating supplier evaluation criteria and seeking diverse sourcing options to avoid disruptions for vulnerable patient groups. These changes have led to innovations in distribution methods, investments in cold-chain logistics, and efforts to streamline regulatory standards across jurisdictions. This evolving environment demands agility in both supply network design and risk management to maintain high levels of patient access.

Methodology & Data Sources

This analysis draws on structured interviews with clinical, procurement, and regulatory leaders, complemented by peer-reviewed studies, industry disclosures, and official regulatory documents. Advanced modeling and policy analysis were used to validate trends and generate actionable segment insights for senior stakeholders.

Why This Report Matters

  • Pinpoint critical strategies to safeguard supply, enhance clinical adoption, and adapt to evolving technology and policy trends across core geographies and therapy areas.
  • Leverage comprehensive segmentation to align operational and commercialization plans with the needs of priority markets, factoring in unique regional and provider dynamics.
  • Develop agile responses to tariffs, regulatory changes, and shifting reimbursement structures by accessing targeted risk mitigation and scenario planning insights.

Conclusion

The coagulation factor concentrates market requires evidence-based, cross-functional strategies. Leaders who focus on continuous innovation, adaptable operations, and robust payer-provider collaborations will secure reliable access and support sustainable growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Coagulation Factor Concentrates Market, by Product Type
8.1. Plasma Derived
8.2. Recombinant
8.2.1. Extended Half Life
8.2.2. Standard Half Life
9. Coagulation Factor Concentrates Market, by Indication
9.1. Hemophilia A
9.1.1. Mild
9.1.2. Moderate
9.1.3. Severe
9.2. Hemophilia B
9.2.1. Mild
9.2.2. Moderate
9.2.3. Severe
9.3. Von Willebrand Disease
9.3.1. Type I
9.3.2. Type II
9.3.3. Type III
10. Coagulation Factor Concentrates Market, by Formulation
10.1. Liquid
10.2. Lyophilized Powder
11. Coagulation Factor Concentrates Market, by End User
11.1. Hospitals
11.2. Specialty Centers
12. Coagulation Factor Concentrates Market, by Distribution Channel
12.1. Hospital Pharmacies
12.2. Online Pharmacies
12.3. Retail Pharmacies
13. Coagulation Factor Concentrates Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Coagulation Factor Concentrates Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Coagulation Factor Concentrates Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Coagulation Factor Concentrates Market
17. China Coagulation Factor Concentrates Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Bayer AG
18.6. Bio Products Laboratory Limited
18.7. BIOGEN INC.
18.8. Biotest AG.
18.9. Cerus Corporation
18.10. CSL Limited
18.11. Emergent BioSolutions Inc.
18.12. Grifols, S.A.
18.13. Kedrion S.p.A
18.14. LFB USA
18.15. Medscape Network
18.16. Novo Nordisk A/S
18.17. Octapharma AG
18.18. Pfizer Inc.
18.19. Sanofi S.A.
18.20. Takeda Pharmaceutical Company Limited
18.21. Thermo Fisher Scientific Inc.
List of Figures
FIGURE 1. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY EXTENDED HALF LIFE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY STANDARD HALF LIFE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY REGION, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY GROUP, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MILD, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY REGION, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY GROUP, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE I, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE II, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY TYPE III, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SPECIALTY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 82. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 83. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 84. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 85. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 86. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 87. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 88. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 89. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 90. AMERICAS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 91. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 93. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 94. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 95. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 96. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 97. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 98. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 99. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 100. NORTH AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 101. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 102. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 103. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 104. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 105. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 106. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 107. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 108. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 109. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 110. LATIN AMERICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 121. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 122. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 123. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 124. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 125. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 126. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 127. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 128. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 129. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. EUROPE COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 131. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 132. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 133. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 134. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 135. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 136. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 137. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 138. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 139. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 140. MIDDLE EAST COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 141. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 142. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 143. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 144. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 145. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 146. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 147. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 148. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 149. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 150. AFRICA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 151. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 152. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 153. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 154. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 155. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 156. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 157. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 158. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 159. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 160. ASIA-PACIFIC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 161. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 162. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 163. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 164. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 165. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 166. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 167. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 168. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 169. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 170. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 171. ASEAN COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 172. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 173. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 174. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 175. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 176. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 177. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 178. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 179. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 180. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 181. GCC COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 191. EUROPEAN UNION COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 192. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 193. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 194. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 195. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 196. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 197. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 198. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 199. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 200. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 201. BRICS COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 202. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 203. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 204. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 205. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 206. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 207. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 208. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 209. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 210. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 211. G7 COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 212. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 213. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 214. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 215. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 216. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 217. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 218. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 219. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 220. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. NATO COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 222. GLOBAL COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 224. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 225. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 226. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 227. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 228. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 229. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 230. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 231. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 232. UNITED STATES COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 233. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 234. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
TABLE 235. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
TABLE 236. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
TABLE 237. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA A, 2018-2032 (USD MILLION)
TABLE 238. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY HEMOPHILIA B, 2018-2032 (USD MILLION)
TABLE 239. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY VON WILLEBRAND DISEASE, 2018-2032 (USD MILLION)
TABLE 240. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
TABLE 241. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 242. CHINA COAGULATION FACTOR CONCENTRATES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Coagulation Factor Concentrates market report include:
  • Bayer AG
  • Bio Products Laboratory Limited
  • BIOGEN INC.
  • Biotest AG.
  • Cerus Corporation
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Grifols, S.A.
  • Kedrion S.p.A
  • LFB USA
  • Medscape Network
  • Novo Nordisk A/S
  • Octapharma AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages185
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 10.4 Billion
Forecasted Market Value ( USD ) by 2032 $ 17.14 Billion
Compound Annual Growth Rate8.6%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Recombinant Coagulation Factor Concentrate Market - Global Forecast 2025-2030 - Product Image

Recombinant Coagulation Factor Concentrate Market - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Coagulation Factor Concentrates - Global Strategic Business Report - Product Image

Coagulation Factor Concentrates - Global Strategic Business Report

  • Report
  • 254 Pages
  • Global
From
Coagulation Factor Deficiency Market - A Global and Regional Analysis: Focus on Deficiency Type, Product Type, End-User, and Region - Analysis and Forecast, 2025-2035 - Product Image

Coagulation Factor Deficiency Market - A Global and Regional Analysis: Focus on Deficiency Type, Product Type, End-User, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 110 Pages
  • Global
From
Recombinant Coagulation Factors - Global Strategic Business Report - Product Image

Recombinant Coagulation Factors - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Coagulation Factor Deficiency Epidemiology Forecast 2025-2034 - Product Image

Coagulation Factor Deficiency Epidemiology Forecast 2025-2034

  • Report
  • 150 Pages
  • Global
From

About the Coagulation Factor Market

The Coagulation Factor market is a segment of the Hematological Drugs market, which includes drugs used to treat blood-related disorders. Coagulation Factors are proteins that help the body form blood clots, and are used to treat conditions such as hemophilia, von Willebrand disease, and other bleeding disorders. These drugs are typically administered intravenously, and are often used in combination with other treatments. The Coagulation Factor market is highly competitive, with a number of companies offering products for the treatment of bleeding disorders. Some of the major players in the market include Pfizer, Novo Nordisk, Bayer, CSL Behring, and Shire. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.